AbbVie Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "End-Period-Cash-Flow" stands at 22.80 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 09/30/2017.
AbbVie Inc's third quarter result of 5.63 Billion USD for the item "End Period Cash Flow" represents a decrease of -12.96 percent compared to it's second quarter result.
Also, AbbVie Inc's third quarter result of 5.63 Billion USD for the item "End Period Cash Flow" represents a decrease of -22.43 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), AbbVie Inc's third quarter result of 22.80 Billion USD for the item "End Period Cash Flow" represents a decrease of -6.67 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -55.54 percent compared to the value the year prior.
The 1 year change in percent is -55.54.
The 3 year change in percent is -37.03.
The 5 year change in percent is -76.00.
The 10 year change in percent is -30.67.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - End Period Cash Flow | 905,699,262,464.00 |
![]() | Johnson & Johnson - End Period Cash Flow | 486,508,953,600.00 |
![]() | Roche Holding AG - End Period Cash Flow | 317,433,206,677.55 |
![]() | AstraZeneca PLC - End Period Cash Flow | 280,205,508,085.11 |
![]() | Novartis AG - End Period Cash Flow | 255,096,620,580.91 |